Welcome

This CME-accredited CME Snapshot™ seven-part series is intended for interventional cardiologists, other cardiologists, lipidologists, endocrinologists, and other diabetologist physicians involved in the ongoing management of patients with persistent hypercholesterolemia.

During these quick-hitting activities, expert faculty will participate in a series of interactive discussions on the latest evidence and their clinical experience managing patients with persistently elevated low-density lipoprotein cholesterol (LDL-C) levels using nonstatin lipid-lowering medications, including inhibitors of the enzyme protein convertase subtilisin/kexin type 9 (PCSK9). Physicians can complete all 7 video modules for a total of 2.0 AMA PRA Category 1 Credits™.

  • Hot Topics in Dyslipidemia From the 2018 American College of Cardiology Scientific Sessions

    Module 1


    Faculty: Deepak L. Bhatt, MD, MPH and Christopher P. Cannon, MD

    Credits: 0.5 AMA PRA Category 1 Credit™

  • Novel Nonstatin LDL-C Targets in High-Risk Patient

    Module 3


    Faculty: TBD

    Credits: 0.25 AMA PRA Category 1 Credit™

  • Collaborating with Patients to Reduce Long-Term Hypercholesterolemia Risks

    Module 5


    Faculty: TBD

    Credits: 0.25 AMA PRA Category 1 Credit™

  • Pharmacoeconomic Outcomes of Suboptimal LDL-C Management

    Module 7


    Faculty: TBD

    Credits: 0.25 AMA PRA Category 1 Credit™

  • Individualizing LDL-C Targets in High Risk Patients
     

    Module 2


    Faculty: TBD

    Credits: 0.25 AMA PRA Category 1 Credit™

  • Long-Term CV Outcomes Trials with PCKS9 Inhibitors

    Module 4


    Faculty: TBD

    Credits: 0.25 AMA PRA Category 1 Credit™

  • Tailored Lipid-Lowering Regiments for Specific Very High-Risk Profiles

    Module 6


    Faculty: TBD

    Credits: 0.25 AMA PRA Category 1 Credit™